techniques that form precisely controlled vascular connections.
The Optiflow™ family of sutureless anastomotic connectors provides
a fast and repeatable method for connecting vessels.
Bioconnect is initially focused on improving vascular access in End Stage
Renal Disease (ESRD) patients who undergo hemodialysis. There are over two
million patients suffering from ESRD. The American Society of Nephrology
and the US Renal Data System have called ESRD a "worldwide plague."
Optiflow technology is currently being utilized to improve the performance of arteriovenous fistulae and vascular access grafts. The Optiflow™ platform optimizes hemodynamics while minimizing vessel trauma.
Long-term results for current vascular access methods are unacceptable. Vascular access is widely recognized as the Achilles Heel of dialysis. Recent studies demonstrate over 60% of newly created AVF access sites fail within the first 4-5 months while 77% of synthetic grafts fail within the first year.